This site is intended for healthcare professionals

Efficacy 0f Repatha across high-risk patient populations reinforced at ACC.21

Read time: 1 mins
Last updated:28th Jun 2021
Published:12th May 2021
Amgen announced the presentation of four cardiovascular research abstracts, including final data from the Repatha (evolocumab) open label extension trial of patients living with HIV who have high cholesterol as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events, including complex revascularization procedures.
Condition: HIV + Dyslipidemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest